L755507

CAT: 0804-HY-19334-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-19334-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
L755507 is a potent, selective agonist of β3-AR with an IC50 of 35 nM. L755507 enhances the homology-directed repair (HDR) -mediated genome editing[1][2][3].
CAS Number
[159182-43-1]
UNSPSC
12352005
Target
Adrenergic Receptor; CRISPR/Cas9
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; GPCR/G Protein; Neuronal Signaling
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/L755507.html
Purity
98.89
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=S(C1=CC=C(NC(NCCCCCC)=O)C=C1)(NC2=CC=C(CCNC[C@H](O)COC3=CC=C(O)C=C3)C=C2)=O
Molecular Formula
C30H40N4O6S
Molecular Weight
584.73
References & Citations
[1]Sato M, et al. The beta3-adrenoceptor agonist 4-[[ (Hexylamino) carbonyl]amino]-N-[4-[2-[[ (2S) -2-hydroxy-3- (4-hydroxyphenoxy) propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S) -N-[4-[2-[[3-[3- (acetamidomethyl) phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human beta3-adrenoceptor. Mol Pharmacol. 2008 Nov;74 (5) :1417-28.|[2]Guoling Li, et al. Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells. Sci Rep. 2017; 7: 8943.|[3]Murakami Y, et al. An effective double gene knock-in strategy using small-molecule L755507 in the medaka fish (Oryzias latipes) . Genesis. 2022;60 (1-2) :e23465.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName

Popular Products